Literature DB >> 29976630

Effects of Sepantronium Bromide (YM-155) on the Whole Transcriptome of MDA-MB-231 Cells: Highlight on Impaired ATR/ATM Fanconi Anemia DNA Damage Response.

Elizabeth A Mazzio1, Charles A Lewis1, Rashid Elhag1, Karam F Soliman2.   

Abstract

Sepantronium bromide (YM-155) is believed to elicit apoptosis and mitotic arrest in tumor cells by reducing (BIRC5, survivin) mRNA. In this study, we monitored changes in survivin mRNA and protein after treating MDA-MB-231 cells with YM-155 concurrent with evaluation of whole transcriptomic (WT) mRNA and long intergenic non-coding RNA at 2 time points: 8 h sub-lethal (83 ng/mL) and 20 h at the LC50 (14.6 ng/mL). The data show a tight association between cell death and the precipitating loss of survivin protein and mRNA (-2.67 fold-change (FC), p<0.001) at 20 h, questioning if the decline in survivin is attributed to cell death or drug impact. The meager loss of survivin mRNA was overshadowed by enormous differential change to the WT in both magnitude and significance for over 2000 differentially up/down-regulated transcripts: (+22 FC to -12 FC, p<0.001). The data show YM-155 to up-regulate transcripts in control of circadian rhythm (NOCT, PER, BHLHe40, NFIL3), tumor suppression (SIK1, FOSB), histone methylation (KDM6B) and negative feedback of NF-kappa B signaling (TNFAIP3). Down-regulated transcripts by YM-155 include glucuronidase (GUSBP3), numerous micro-RNAs, DNA damage repair elements (CENPI, POLQ, RAD54B) and the most affected system was the ataxia-telangiectasia mutated (ATM)/Fanconi anemia E3 monoubiquitin ligase core complexes (FANC transcripts - A/B/E/F/G/M), FANC2, FANCI, BRCA1, BRCA2, RAD51, PALB2 gene and ATR (ATM- and Rad3-Related) pathway. In conclusion, these findings suggest that a primary target of YM-155 is the loss of replicative DNA repair systems. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Fanconi anemia; Sepantronium bromide; YM-155; transcriptome

Mesh:

Substances:

Year:  2018        PMID: 29976630      PMCID: PMC6070710          DOI: 10.21873/cgp.20083

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   3.395


  117 in total

1.  Polo-like kinase-activating kinases: Aurora A, Aurora B and what else?

Authors:  Vincent Archambault; Mar Carmena
Journal:  Cell Cycle       Date:  2012-04-15       Impact factor: 4.534

2.  FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas.

Authors:  Karin Milde-Langosch; Holger Kappes; Sabine Riethdorf; Thomas Löning; Ana-Maria Bamberger
Journal:  Breast Cancer Res Treat       Date:  2003-02       Impact factor: 4.872

3.  Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.

Authors:  Minghui Zhang; Xiaosan Zhang; Shu Zhao; Yan Wang; Wenyu Di; Gangling Zhao; Maopeng Yang; Qingyuan Zhang
Journal:  Target Oncol       Date:  2014-12       Impact factor: 4.493

Review 4.  Control of DNA replication licensing in a cell cycle.

Authors:  Hideo Nishitani; Zoi Lygerou
Journal:  Genes Cells       Date:  2002-06       Impact factor: 1.891

5.  BRCA1 downregulates the kinase activity of Polo-like kinase 1 in response to replication stress.

Authors:  Jianqiu Zou; Khosrow Rezvani; Hongmin Wang; Kyung S Lee; Dong Zhang
Journal:  Cell Cycle       Date:  2013-07-15       Impact factor: 4.534

6.  Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.

Authors:  Ying Yu; Xiaosu Zhao; Yu Zhang; Yanling Kang; Jiaqi Wang; Yingchun Liu
Journal:  Oncol Rep       Date:  2015-05-05       Impact factor: 4.136

7.  Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents.

Authors:  Dong Wha Jun; Mihwa Hwang; Hyun Jung Kim; Soo Kyung Hwang; Sunshin Kim; Chang-Hun Lee
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

8.  Identification of potential therapeutic targets for colorectal cancer by bioinformatics analysis.

Authors:  Ming Yan; Maomin Song; Rixing Bai; Shi Cheng; Wenmao Yan
Journal:  Oncol Lett       Date:  2016-10-31       Impact factor: 2.967

9.  Altered expression of Tumor Necrosis Factor Alpha -Induced Protein 3 correlates with disease severity in Ulcerative Colitis.

Authors:  Ishani Majumdar; Vineet Ahuja; Jaishree Paul
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

10.  TNFAIP3 gene rs7749323 polymorphism is associated with late onset myasthenia gravis.

Authors:  Hong-Wei Yang; Yanchen Xie; Yuan Zhao; Liang Sun; Xiaoquan Zhu; Shuhui Wang; Yong-Qiang Zhang; Ping Lei; Yunxiao Meng
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

View more
  3 in total

1.  DNA Repair Genes as Drug Candidates for Early Breast Cancer Onset in Latin America: A Systematic Review.

Authors:  Laura Keren Urbina-Jara; Emmanuel Martinez-Ledesma; Augusto Rojas-Martinez; Francisco Ricardo Rodriguez-Recio; Rocio Ortiz-Lopez
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

Review 2.  Effect of Sepatronium Bromide (YM-155) on DNA Double-Strand Breaks Repair in Cancer Cells.

Authors:  Dusana Majera; Martin Mistrik
Journal:  Int J Mol Sci       Date:  2020-12-11       Impact factor: 6.208

3.  Targeted-Gene Sequencing and Bioinformatics Analysis of Patients with Pancreatic Mucoepidermoid Carcinoma: A Case Report and Literature Review.

Authors:  Zhitao Chen; Lele Zhang; Jiacheng Huang; Chenchen Ding; Ting Zhang; Dalong Wan; Liang Xue
Journal:  Onco Targets Ther       Date:  2021-06-03       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.